What Women Are Never Told About Early Menopause After Cancer
Dr. Connie Menn was diagnosed with breast cancer at 28 and pushed into premature menopause — an experience that became her life's work. She explains how cancer treatment strips estrogen from the whole body, why that collateral damage is almost never managed, and how women can advocate for individualized care. The conversation covers estrogen receptor biology, tamoxifen versus aromatase inhibitors, genetic testing, and the wide range of options that exist between suffering in silence and full hormone therapy.
Overview
Dr. Connie Menn joins Louisa Nicola to talk about a group of women the health system largely overlooks: those pushed into early or premature menopause by cancer treatment, ovary removal, or genetics. She opens with her own story — a lump dismissed at 28, a mother lost to ovarian cancer, and a stage 2A diagnosis right before Christmas 2001.
Because roughly 80% of breast cancers are estrogen receptor positive, the mainstay of treatment is to block or strip out estrogen, which leaves a growing population of long-term survivors living for decades in deep estrogen deprivation. She dismantles the idea that estrogen causes breast cancer, explaining that receptors exist throughout the body and that a tumor keeping its receptor is not the same as estrogen creating the disease.
The discussion walks through how tamoxifen works as a selective modulator versus how aromatase inhibitors push estrogen to near zero, and why the two produce very different experiences. She also covers genetic testing gaps, the case for repeating risk assessments over time, and why women tested before 2013 may need updated panels. A recurring theme is that nobody owns this patient after the oncologist declares her cancer free. Her closing argument is that ovarian function should be valued for far more than fertility.
Key quotes
5At her funeral, I said to myself, well, maybe I should get that lump checked out.
80% of women who are diagnosed with breast cancer actually don't have a strong family history.
It doesn't mean that the estrogen caused the cancer.
You have to be your own CEO, because no one's coming to save you when it comes to this topic.
I just would wish that we would value ovarian function beyond our reproductive capacity.
Key ideas
9A personal story that became a mission
At 28, as a second-year OB-GYN resident, she felt a lump and was told she was too young for breast cancer. Her mother died of ovarian cancer after a delayed diagnosis, and she was diagnosed with stage 2A ER/PR positive disease right before Christmas 2001. Premature menopause at 28 was something nobody had prepared her for.
Rates are rising fastest in the youngest women
Breast cancer rates are climbing in premenopausal women, and fastest in women under 30. That produces a larger and younger population of survivors who live many more years with the consequences of estrogen deprivation.
Every breast cancer is different
Breast cancer is heterogeneous — she tells patients it is as unique as a fingerprint. The problem is that all patients get lumped into one bucket when it comes to managing menopause, when management should be as individualized as the cancer itself.
Genetic testing has moved on, and old results may be stale
Her own initial test was negative, and updated panel testing years later showed she carried a BRCA2 mutation, because full gene rearrangement analysis was not standard before 2013. Consumer ancestry kits are not equivalent to medical-grade genetic testing, and the gene list now extends well beyond BRCA1 and BRCA2.
Previvors are left without follow-through
Carriers who have never had cancer are advised to have their ovaries removed once childbearing is complete. She notes that many delay because nobody is helping them manage the surgical menopause that follows, and support after that surgery is rarely offered without a fight.
Estrogen receptors are everywhere
Estrogen receptors sit in the brain, skin, bone and breast tissue, in men and children too. A tumor that keeps or overexpresses that receptor can use it to grow, but that is a very different statement from saying estrogen caused the disease — a distinction that shapes how women feel about their own bodies.
Risk is more than a hormone story
Pregnancy involves very high estrogen and is protective, and breastfeeding changes breast tissue in protective ways. She points instead to inflammation, alcohol, environmental exposures, chronic stress and body composition — arguing that reducing everything to estrogen good or estrogen bad misses the real picture.
Tamoxifen blocks receptors without ending ovarian function
As a selective estrogen receptor modulator, tamoxifen blocks receptors in breast tissue while acting as an agonist in others such as the uterus. It can cause menopause-like symptoms including hot flashes, sleep disruption and cognitive changes, but it does not lower estrogen levels or cause permanent menopause.
Aromatase inhibitors take estrogen close to zero
These require a menopausal state and prevent androgens from being converted to estrogens throughout the body. She describes the result as putting estrogen in the basement — highly effective against the cancer, but a profound deprivation with consequences for bone, brain, heart, muscle and sexual function.
Practical takeaways
7- 1
Start risk assessment early and repeat it 13:00
A thorough family history and lifestyle conversation can begin around age 25, and it should be revisited as your family history and breast findings change over time.
- 2
Ask whether your genetic testing needs updating 19:30
If you or a relative were tested before 2013, or only for BRCA1 and BRCA2, a modern panel with a genetic counselor may reveal information that older testing could not.
- 3
Separate your biology from your guilt 31:00
Receptor status describes the tumor, not a verdict on your birth control, your pregnancies or your breastfeeding history. Letting go of that guilt makes clearer decisions possible.
- 4
Know exactly which medication you are on and what it does 43:00
Tamoxifen and aromatase inhibitors work in completely different ways, so the symptoms and the support you need differ too. Understanding the mechanism is what makes a real conversation with your clinician possible.
- 5
Do not accept a kitchen cupboard as a plan 1:02:00
She is not against a simple moisturizer, but she is clear that a moisturizer will not address tissue changes, blood flow, recurrent urinary infections or night-time waking — and there are guideline-supported options worth asking about.
- 6
Connect the symptoms to the bigger picture 1:04:00
Unmanaged hot flashes, night sweats and insomnia disturb sleep, mood and intimacy, and those things do not stay in their own lane. Treating them is part of protecting long-term brain and cardiovascular health.
- 7
Curate your team, and be willing to change it 1:07:30
Who you start with is not always who you stay with. Look for clinicians who will explain the limits of the evidence and still help you make an informed choice.
Topics & chapters
15The women nobody is looking after
Rising rates in young women, and the reality that most survivors have nowhere to go for menopause care.
Diagnosed at 28
A dismissed lump, her mother's death from ovarian cancer, and a stage 2A diagnosis before Christmas 2001.
Survival is up, collateral damage is unmanaged
About 80% of breast cancers are estrogen receptor positive, producing a growing group of long-term survivors in deep estrogen deprivation.
What breast cancer actually is
Heterogeneity, why one bucket does not fit all patients, and the case for repeated risk assessment from about age 25.
Genes beyond BRCA1 and BRCA2
Medical-grade testing versus consumer kits, her own negative-then-positive result, and how few people get referred to a genetic counselor.
Ovaries, previvors and timing
Why carriers are advised to remove their ovaries, why many delay, and the case for full hormone support to at least the age of natural menopause.
The biology of estrogen
Receptors throughout the body, what receptor positive really means, and why fear and guilt are the wrong takeaways.
Beyond estrogen good, estrogen bad
Pregnancy and breastfeeding as protective, the alcohol conversation, the soy myth, and the many factors behind rising rates.
Tamoxifen explained
How a selective modulator blocks in one tissue and promotes in another, what it does to symptoms, and why it does not mean permanent menopause.
Aromatase inhibitors
Why they require a menopausal state, how they drive estrogen to near zero, and how duration is decided by risk features.
Who owns this patient?
The oncologist declares cure, the gynecologist declines, and the survivorship gap that leaves women navigating alone.
How many women this affects
Premature and early menopause numbers, hysterectomy and blood flow, and the groups least likely to be offered help.
The coconut oil problem
Why moisturizers are offered as first line, what they cannot do, and how genital and urinary symptoms connect to sleep, mood and relationships.
Hormone therapy after breast cancer
The individualized approach, the 2026 consensus review in the menopause literature, and the triple negative case that makes blanket rules look absurd.
A story that ends well, and one closing wish
A friend who struggled for two years and now thrives, and a plea to value ovarian function beyond fertility.